금융 뉴스 허브
실시간 글로벌 금융 시장 뉴스 · 분석 · 인사이트
BREAKING주요 뉴스
Euro: Gradual upside as Fed and ECB converge – Commerzbank
Commerzbank economists, led by Dr. Jörg Krämer and colleagues, expect the Fed and ECB to keep rates ...
Gold slides to a 3-month low below $4,000: 3 analysts agree it's under pressure, and disagree on the floor
Gold (XAU/USD) has tumbled below $4,000 to a fresh three-month low as surging Oil prices revive infl...
The IMF Just Raised Its Economic Growth Forecast. Buried in the Report Is a Warning for Stock Investors.
Economic growth is becoming increasingly reliant on one theme and a smaller number of economies....
3 Reasons Investors Love Diamondback Energy (FANG)
Diamondback Energy has been treading water for the past six months, recording a small return of 1.8% while holding steady at $192.41. The stock also fell short of the S&P 500’s 12.8% gain during that ...
Lynas unveils plans to build Brazil rare earths plant - Mining.com
Update: US Equity Indexes Mixed After Ukraine-Russia Energy Ceasefire Struggles to Take Off
(Updates with index/price moves and geopolitical news from the first paragraph.) US equity indexe
3 Unprofitable Stocks Walking a Fine Line
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Lockheed Martin's Sikorsky unveils containerized drone deployment system
S&P 500 expected to see 25% EPS growth as earnings kick off
Johnson & Johnson earnings on deck: What to expect
Top S&P 500 stocks soar over 2,000% since 2022 low
SCHD Is Down 6% From Its Peak. Here's Why History Says It's Still a Buy.
Even if the S&P 500 goes into a sell-off, dividend stocks could have more room to grow.
Google release details on the new Fitbit Edge fitness tracker
ROTH’s top October ETFs: Semiconductor and technology funds lead Quant rankings
Parkinson’s cell therapy developer files to go public
Aspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a patient's own cells into dopamine-producing neurons.